As of October 2026, only one major HSV-2 vaccine is still being tested in people: BioNTech’s preventive mRNA vaccine BNT163, in an early Phase 1 trial. Moderna and GSK both stopped their vaccines for people who already have HSV-2. No herpes vaccine has passed a Phase 3 trial. A realistic timeline for any vaccine reaching patients is 5 to 10 years or more, and gene therapy aimed at a cure is still in animal studies. The one new treatment that has arrived is a drug, not a vaccine: Hovilpri, approved in October 2026 for resistant herpes in people with weak immune systems.
Why HSV-2 vaccine development is hard
There have been HSV vaccine candidates since the 1980s. Most failed in clinical trials. Understanding why is important context for evaluating current efforts.
HSV-2 presents specific challenges. First, it establishes latency in nerve ganglia, hiding from the immune system in a location that's difficult to access. Second, HSV has evolved sophisticated immune evasion mechanisms, including ways to block interferon signaling and avoid being "seen" by immune cells. Third, the immune responses that protect against other viruses don't work as well here. Antibody-based protection (which many vaccines target) isn't sufficient on its own.
The most notorious failure was Herpevac. Two earlier trials of the same GSK vaccine had found about 73 to 74% protection, but only in women who had never had HSV-1 or HSV-2, and none in men or in women who already had HSV-1 (source). Herpevac was the big follow up, testing it in 8,323 women who had neither virus. It did not protect against HSV-2 at all. The only benefit was 58% protection against genital HSV-1 (source). The results, published in 2012, dampened enthusiasm for years.
But the field has learned from those failures, and new approaches are more targeted and sophisticated.
mRNA vaccine approaches
The COVID-19 vaccine success demonstrated that mRNA technology could rapidly generate effective vaccines against viral pathogens. Two big companies applied it to HSV-2, and by October 2026 only one of them is still going.
mRNA vaccines can be designed to target multiple HSV proteins simultaneously, including those involved in immune evasion that previous vaccine approaches couldn't address effectively. Early results in animals were encouraging. In people, BioNTech’s preventive vaccine BNT163 enrolled 318 participants in a Phase 1 trial that is active but no longer recruiting, with completion expected in October 2026 (source). Phase 1 tests safety and immune response, not whether it prevents infection.
The advantage of mRNA approaches: they can be designed, manufactured, and adjusted relatively quickly compared to traditional vaccine development. The challenge: animal model success hasn't always translated to humans for HSV, which is why keeping expectations calibrated matters.
Therapeutic vaccines: for people already infected
A therapeutic vaccine would be different from a preventive vaccine. Rather than preventing initial infection, it would train the immune system of people already carrying HSV-2 to better control the virus, reducing outbreaks and transmission. This would be huge for the roughly 520 million people already infected.
This is where the field has had its hardest recent setbacks. Early human trials showed that therapeutic vaccines can boost HSV-specific immune responses, but turning that into fewer outbreaks has not worked so far. GSK’s therapeutic vaccine, GSK3943104, failed its main goal in a 240 person Phase 2 trial and was stopped in September 2024 (source). Moderna’s therapeutic mRNA vaccine, mRNA-1608, showed only a trend toward fewer outbreaks in Phase 1/2, and Moderna ended development in November 2025 (source).
For people who already have HSV-2, the most promising work right now is not a vaccine but longer acting antiviral pills, including a once a week pill that cut shedding by 94% in a small trial. Our vaccine and cure tracker follows each program month by month.
Gene therapy and cure approaches
The idea of actually eliminating latent HSV from nerve ganglia is the holy grail. And it's genuinely being researched, just at a very early stage.
CRISPR gene editing has been explored as a way to target and disrupt HSV DNA in latently infected cells. Laboratory research has shown it's possible to reduce latent viral load in animal models. But delivering CRISPR editing tools specifically to nerve ganglia in humans is a significant technical challenge, and safety considerations around gene editing in human neurons are substantial.
The strongest result so far came from Fred Hutch in Seattle in 2024: in mice, a gene editing treatment removed about 90% of HSV-1 after a facial infection and 97% after a genital infection (source). That work was on HSV-1, the team is still adapting it for HSV-2, and no person has received it. These are exciting findings in the lab but are years from clinical availability.
Honest timeline
Okay, you want to know when something will actually help you. Here's the honest answer.
A preventive vaccine (for people not yet infected): realistically 5-10+ years from meaningful clinical availability, assuming current trials go well. That's if things go well. Previous vaccine failures happened at late stages, so caution is warranted.
A therapeutic vaccine (for people already infected): at least as long, and arguably longer after the GSK and Moderna setbacks, since neither of the two most advanced candidates is still in development. Better antiviral pills are likely to arrive first.
An actual cure (eliminating latent virus): much further away. We're talking 10-20+ years for something realistic, assuming gene therapy approaches continue to advance. This isn't pessimism, it's just the state of the science.
What this means for you right now: the tools available today (antivirals, risk reduction strategies) are genuinely effective. Many people manage HSV-2 comfortably with current treatments. Future developments are worth following, but current treatment makes life with HSV-2 very manageable right now.
Where to follow research updates
If you want to track ongoing research, ClinicalTrials.gov lists current HSV vaccine and treatment trials. Search for "herpes simplex virus" to see what's actively recruiting. Research institutions like Fred Hutch Cancer Center in Seattle, home to several of the leading herpes research groups, publish updates on HSV research regularly. We summarise every active program on our vaccine and cure tracker.
Frequently asked questions
Is there an HSV-2 vaccine in development?
Yes, but fewer than before. As of October 2026 the main one still in human testing is BioNTech’s preventive mRNA vaccine BNT163, in Phase 1. Moderna and GSK stopped their therapeutic vaccines in 2025 and 2024. No herpes vaccine has passed a Phase 3 trial.
When will an HSV-2 vaccine be available?
Honest answer: at least 5-10 years for a preventive vaccine, if current trials go well. The history of HSV vaccine development includes late-stage failures, so realistic caution is warranted. Current antivirals are highly effective in the meantime.
Why is an HSV-2 vaccine so difficult to develop?
HSV-2 establishes latency in nerve ganglia where the immune system has limited access. It's evolved sophisticated immune evasion mechanisms. Previous approaches that worked for other viruses didn't work for HSV-2. The mRNA approach is promising because it can target multiple viral proteins, including immune evasion proteins.
Is there a cure for HSV-2?
Not yet. Current antivirals suppress the virus effectively but don't eliminate latent viral DNA. Gene therapy approaches that could theoretically remove latent HSV DNA from nerve cells are in very early research stages. Meaningful clinical application is likely 10-20+ years away.
Related: Current treatment options | Vaccine research article | Is there a cure? | Vaccine and cure tracker